Core Insights - Harbour BioMed has exercised its warrant to acquire common stock in Spruce Biosciences, holding approximately 3.8% of total outstanding shares and 3.1% of fully diluted shares of Spruce [1][3] Company Overview - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology [4] - The company is enhancing its pipeline through internal R&D, strategic global collaborations, and selective acquisitions [4] Collaboration Details - The warrant was issued in connection with a license and collaboration agreement between HBM Alpha Therapeutics and Spruce, aimed at advancing the development of SPR202, a monoclonal antibody for various disorders [2] - This collaboration signifies a shift from a traditional licensor-licensee relationship to a strategic partnership, emphasizing a shared commitment to developing transformative therapies [3]